Printer Friendly

ZANTAC PATENT TRIAL CONCLUDES

 ELIZABETH CITY, N.C., Aug. 18 /PRNewswire/ -- Glaxo today presented closing arguments in the company's lawsuit against Novopharm Ltd., a generic drug company based in Canada, involving ranitidine hydrochloride, the active ingredient in Zantac(R), Glaxo's popular anti- ulcer medication.
 Novopharm, which has filed an Abbreviated New Drug Application for ranitidine hydrochloride, has admitted to infringing a U.S. patent that gives Glaxo exclusive rights to a specific crystalline form of ranitidine hydrochloride known as Form 2 until June 2002. An earlier Glaxo patent covering the ranitidine hydrochloride molecule expires in 1995 and is not at issue in the litigation.
 During the eight-day trial, Glaxo presented a series of expert witnesses who disputed Novopharm contentions that the Form 2 patent is invalid. Their testimony supported Glaxo's position that Form 2 ranitidine hydrochloride meets the requirements for patentability, including novelty, and that Glaxo complied with all requirements of U.S. law in obtaining the 2002 patent.
 U.S. law presumes that a patent granted by the U.S. Patent Office is valid. Novopharm has the burden of proving its contentions with clear and convincing evidence. By filing its Abbreviated New Drug Application, Novopharm is seeking the right to market Form 2 ranitidine hydrochloride, which was discovered by Glaxo and is the only form of ranitidine hydrochloride Glaxo has ever commercially manufactured.
 U.S. District Court Judge Terrence Boyle has not set a date for deciding the case. A decision may be issued by the end of the year.
 Glaxo Inc., located in Research Triangle Park, N.C., is the U.S. subsidiary of Glaxo Holdings p.l.c., an international scientific research organization dedicated to the discovery, development, manufacturing and marketing of prescription medicines.
 -0- 8/18/93
 /CONTACT: Rick Sluder, Corporate Communications, Glaxo Inc., 919-248-2839/
 (GLX)


CO: Glaxo Inc; Novopharm Ltd. ST: North Carolina IN: MTC SU:

SB -- CH004 -- 3944 08/18/93 13:37 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 18, 1993
Words:316
Previous Article:MERRY LAND & INVESTMENT COMPANY BUYS ATLANTA PROPERTY
Next Article:BALL CORPORATION TO LAUNCH COMMISSION-FREE SELLING/PURCHASING PROGRAM FOR SMALL SHAREHOLDER ACCOUNTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters